摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Chlor-5,6,7,8-tetrahydro-2-phenyl-chinazolin | 17709-79-4

中文名称
——
中文别名
——
英文名称
4-Chlor-5,6,7,8-tetrahydro-2-phenyl-chinazolin
英文别名
4-chloro-2-phenyl-5,6,7,8-tetrahydro-quinazoline;4-chloro-5,6,7,8-tetrahydro-2-phenylquinazoline;4-Chloro-2-phenyl-5,6,7,8-tetrahydroquinazoline
4-Chlor-5,6,7,8-tetrahydro-2-phenyl-chinazolin化学式
CAS
17709-79-4
化学式
C14H13ClN2
mdl
——
分子量
244.724
InChiKey
GIKHXLGNAKKHBA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2-氨基-N,N-二丙基乙酰胺4-Chlor-5,6,7,8-tetrahydro-2-phenyl-chinazolin三乙胺 作用下, 以 氯仿 为溶剂, 生成 2-(5,6,7,8-tetrahydro-2-phenyl-4-quinazolinylamino)-N,N-dipropylacetamide
    参考文献:
    名称:
    Acetamide derivative, process for preparing the same, and a
    摘要:
    (I)式的乙酰胺衍生物:其中X为--O--或--NR.sub.4 --,R.sub.1为H、低烷基、低烯基或环烷基-低烷基,R.sub.2为低烷基、环烷基、取代或未取代的苯基等,R.sub.3为H、低烷基或羟基-低烷基,R.sub.4为H、低烷基等,R.sub.5为H、低烷基、低烯基、羟基-低烷基等,R.sub.6为H、低烷基、CF.sub.3、取代或未取代的苯基,或R.sub.5和R.sub.6可选择结合形成--(CH.sub.2)n--,R.sub.7为H、卤素、低烷基、低烷氧基、CF.sub.3、OH、NH.sub.2等,R.sub.8为H、卤素、低烷基或低烷氧基,或其药用可接受的酸盐。本发明的化合物选择性作用于外周型BZ.omega..sub.3-受体,表现出优异的药理活性,因此在预防或治疗与焦虑相关的疾病、抑郁症、癫痫等中枢神经系统紊乱方面具有用处。
    公开号:
    US05972946A1
点击查看最新优质反应信息

文献信息

  • NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    申请人:BUCKMAN Brad
    公开号:US20120101032A1
    公开(公告)日:2012-04-26
    The embodiments provide compounds of the general Formulae I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI and VIa, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
    本实施例提供了一般式I、Ia、II、IIa、III、IIIa、IV、IVa、V、Va、VI和VIa的化合物,以及包括药物组成物在内的组合物,其中包括一种主体化合物。本实施例还提供了治疗方法,包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法,该方法通常涉及向需要治疗的个体施用一种主体化合物或组合物的有效量。
  • ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME
    申请人:DAINIPPON PHARMACEUTICAL CO., LTD.
    公开号:EP0826673B1
    公开(公告)日:2002-11-20
  • US5972946A
    申请人:——
    公开号:US5972946A
    公开(公告)日:1999-10-26
  • [EN] NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION<br/>[FR] NOUVEAUX INHIBITEURS MACROCYCLIQUES DE LA RÉPLICATION DU VIRUS DE L'HÉPATITE C
    申请人:INTERMUNE INC
    公开号:WO2012054874A1
    公开(公告)日:2012-04-26
    The embodiments provide compounds of the general Formulae I, la, II, Ila, IIΙ, IIIa, IV, IVa, V, Va, VI and VIa, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
  • Acetamide derivative, process for preparing the same, and a
    申请人:Dainippon Pharmaceutical Co., Ltd.
    公开号:US05972946A1
    公开(公告)日:1999-10-26
    An acetamide derivative of the formula (I): ##STR1## wherein X is --0-- or --NR.sub.4 --, R.sub.1 is H, lower alkyl, lower alkenyl or cyclolalkyl-lower-alkyl, R.sub.2 is lower alkyl, cycloalkyl, substituted or unsubstituted phenyl, etc., R.sub.3 is H, lower alkyl or hydroxy-lower alkyl, R.sub.4 is H, lower alkyl, etc., R.sub.5 is H, lower alkyl, lower alkenyl, hydroxy-lower alkyl, etc., R.sub.6 is H, lower alkyl, CF.sub.3, substituted or unsubstituted phenyl, or R.sub.5 and R.sub.6 may optionally combine to form --(CH.sub.2)n--, R.sub.7 is H, halogen, lower alkyl, lower alkoxy, CF.sub.3, OH, NH.sub.2, etc., R.sub.8 is H, halogen, lower alkyl or lower alkoxy, or a pharmaceutically acceptable acid addition salt thereof. The compounds of the present invention selectively act on the peripheral-type BZ.omega..sub.3 -receptor, and show excellent pharmacological activities, and hence, they are useful in the prophylaxis or treatment of central nervous disorders such as anxiety-related diseases, depression, epilepsy, etc.
    (I)式的乙酰胺衍生物:其中X为--O--或--NR.sub.4 --,R.sub.1为H、低烷基、低烯基或环烷基-低烷基,R.sub.2为低烷基、环烷基、取代或未取代的苯基等,R.sub.3为H、低烷基或羟基-低烷基,R.sub.4为H、低烷基等,R.sub.5为H、低烷基、低烯基、羟基-低烷基等,R.sub.6为H、低烷基、CF.sub.3、取代或未取代的苯基,或R.sub.5和R.sub.6可选择结合形成--(CH.sub.2)n--,R.sub.7为H、卤素、低烷基、低烷氧基、CF.sub.3、OH、NH.sub.2等,R.sub.8为H、卤素、低烷基或低烷氧基,或其药用可接受的酸盐。本发明的化合物选择性作用于外周型BZ.omega..sub.3-受体,表现出优异的药理活性,因此在预防或治疗与焦虑相关的疾病、抑郁症、癫痫等中枢神经系统紊乱方面具有用处。
查看更多